Interhuman transmission as a potential key parameter for geographical variation in the prevalence of Pneumocystis jirovecii dihydropteroate synthase mutations. by Hauser, P.M. et al.
e28 • CID 2010:51 (15 August) • Hauser et al
M A J O R A R T I C L E
Interhuman Transmission as a Potential
Key Parameter for Geographical Variation
in the Prevalence of Pneumocystis jirovecii
Dihydropteroate Synthase Mutations
Philippe M. Hauser,1 Aimable Nahimana,2,a Patrick Taffe,3 Rainer Weber,5 Patrick Francioli,2,4 Jacques Bille,1
and Meja Rabodonirina6
1Institute of Microbiology, 2Hospital Preventive Medicine, 3Data Center, Swiss HIV Cohort Study, and 4Division of Infectious Diseases, Centre
Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, and 5Division of Infectious Diseases, University Hospital and University
of Zurich, Zurich, Switzerland; and 6Laboratory of Parasitology, Hospices Civils de Lyon and University of Lyon, Unite Mixte Recherche 145
(Institut de Recherche pour le De´veloppement and University of Montpellier), Lyon, France
Background. Pneumocystis jirovecii dihydropteroate synthase (DHPS) mutations are associated with failure of
prophylaxis with sulfa drugs. This retrospective study sought to better understand the geographical variation in
the prevalence of these mutations.
Methods. DHPS polymorphisms in 394 clinical specimens from immunosuppressed patients who received a
diagnosis of P. jirovecii pneumonia and who were hospitalized in 3 European cities were examined using polymerase
chain reaction (PCR) single-strand conformation polymorphism. Demographic and clinical characteristics were
obtained from patients’ medical charts.
Results. Of the 394 patients, 79 (20%) were infected with a P. jirovecii strain harboring one or both of the
previously reported DHPS mutations. The prevalence of DHPS mutations was significantly higher in Lyon than
in Switzerland (33.0% vs 7.5%; ). The proportion of patients with no evidence of sulfa exposure whoP ! .001
harbored a mutant P. jirovecii DHPS genotype was significantly higher in Lyon than in Switzerland (29.7% vs
3.0%; ). During the study period in Lyon, in contrast to the Swiss hospitals, measures to prevent dissem-P ! .001
ination of P. jirovecii from patients with P. jirovecii pneumonia were generally not implemented, and most patients
received suboptimal prophylaxis, the failure of which was strictly associated with mutated P. jirovecii. Thus,
nosocomial interhuman transmission of mutated strains directly or indirectly from other individuals in whom
selection of mutants occurred may explain the high proportion of mutations without sulfa exposure in Lyon.
Conclusions. Interhuman transmission of P. jirovecii, rather than selection pressure by sulfa prophylaxis, may
play a predominant role in the geographical variation in the prevalence in the P. jirovecii DHPS mutations.
The circulation of Pneumocystis jirovecii strains among
putative human reservoirs, including patients with P.
jirovecii pneumonia (PCP) and colonized or healthy
adults and infants, remains poorly understood. Com-
prehension of epidemiological patterns of transmission
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and acquisition of P. jirovecii is crucial to improve pre-
vention of the disease. This is also true in developing
countries where PCP is probably a major cause of illness
and death [1, 2]. However, at the present time, diagnosis
of PCP in these countries is mainly clinical, and reliable
studies using bronchoalveolar lavage specimens are
scarce. Thus, most of the data about P. jirovecii epi-
demiology are still expected to come from developed
countries, despite the decrease in the number of PCP
cases, which is related to better access to highly active
antiretroviral therapy.
Most drugs used for prevention and treatment of
PCP target enzymes that are involved in the biosyn-
thesis of folic acid. Sulfa drugs (sulfamethoxazole, dap-
sone, and sulfadoxine) inhibit dihydropteroate synthase
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Table 1. Demographic and Clinical Characteristics of 305 Human Immunodeficiency Virus (HIV)–Positive
and HIV-Negative Patients Who Received a Diagnosis of Pneumocystis jirovecii Pneumonia in Lyon, Lau-
sanne, and Zurich Hospitals
Characteristics
Patients who received
sulfa prophylaxisa
Patients who received
no or other
prophylaxisb Overall
HIV negative 9 64 73 (100)
Age, median years (range) 49 (20–76) 36 (4–82) 55 (4–82)
Sex
Male 8 39 47 (64.4)
Female 1 25 26 (35.6)
HIV positive 25 207 232 (100)
Age, median years (range) 35 (23–56) 36 (4–69) 36 (4–69)
Sex
Male 20 170 190 (82)
Female 5 37 42 (18)
HIV risk factor
Homosexual 14 89 103 (44.4)
Heterosexual 7 58 65 (28)
Injection drug user 2 28 30 (12.9)
Other 2 32 34 (14.7)
CD4 cell count, median cells/mL (range) 9 (0–99) 31 (0–390) 29 (0–390)
Cerebral toxoplasmosis 0 0 0
NOTE. Data are no. (%) of patients, unless indicated otherwise.
a Includes 14 patients who received sulfadoxine-pyrimethamine, 10 patients who received sulfamethoxazole-trimethoprim,
and 10 patients who received dapsone.
b Patients who received prophylaxis with pentamidine ( ) or atovaquone ( ) are included in this category.np 31 np 2
(DHPS), whereas trimethoprim and pyrimethamine target di-
hydrofolate reductase. Cotrimoxazole, the combination of sul-
famethoxazole and trimethoprim, is the drug of choice, whereas
Fansidar, the combination of sulfadoxine and pyrimethamine,
is rarely used. In the past, several studies reported the associ-
ation between failure of sulfa prophylaxis or exposure to sulfa
drugs and substitutions of 2 amino acids within the putative
sulfa binding site of DHPS at positions 55 (threonine to alanine;
mutation M1) and 57 (proline to serine; M2) [3–5]. They are
observed either as single mutations (M1 or M2) or a double
mutation (M3). The P. jirovecii DHPS sequence with no sub-
stitutions was defined as the wild type.
The DHPS mutations not only raise questions about the
acquisition of resistance to sulfa drugs by P. jirovecii but also
can be useful as an epidemiological marker to investigate P.
jirovecii circulation among its reservoirs. The characterization
of the parameters influencing the geographic variation in allelic
frequency at the DHPS locus may prove to be informative. We
therefore analyzed this locus in a large collection of clinical
specimens from 3 Western European cities and focused on the
epidemiological implications of the results. (Preliminary results
of this study were presented as a short note in a conference
proceeding [6].)
PATIENTS, MATERIALS, AND METHODS
Patients and specimens. A total of 394 human immunode-
ficiency virus (HIV)–negative and HIV-infected patients who
received a diagnosis of PCP and who were hospitalized at 1 of
the 7 hospitals in 3 distinct European cities are included in this
study. Five hospitals were in Lyon (France), and 2 were in
Switzerland (Centre Hospitalier Universitaire Vaudois in Lau-
sanne and University Hospital in Zurich). Diagnosis of PCP
was performed by methenamine silver staining in Lyon and
Lausanne and by immunostaining in Zurich (Dako). Consent
was obtained from all patients. Study protocols and patient
consent forms were approved by each site’s institutional review
board. Lyon is ∼400 km from Zurich, and Lausanne is located
at approximately mid-distance between Lyon and Zurich. Lyon,
Zurich, and Lausanne include 1.75, 1.1, and 0.3 million in-
habitants, respectively. The 394 bronchoalveolar lavage speci-
mens were collected from April 1993 to November 1997 for
Lyon’s hospitals, from October 1990 to February 2000 for the
Lausanne hospital, and in June 1991 as well as from August
1994 to October 1998 for the Zurich hospital. Part of the 194
specimens from Lyon were analyzed previously to study the
association of DHPS mutations with different prophylactic sulfa
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Table 2. Pneumocystis jirovecii Dihydropteroate Synthase
(DHPS) Genotypes of 394 Human Immunodeficiency Virus (HIV)–
Negative and HIV-Positive Patients Who Received a Diagnosis
of P. jirovecii Pneumonia in 3 European Cities
DHPS genotype Lyon Lausanne Zurich
WT 130 (67.0) 131 (93.6) 54 (90.0)
Mutant
M1 0 (0) 2 (1.4) 0 (0)
M2 32 (16.5) 0 (0) 0 (0)
M3 9 (4.6) 2 (1.4) 2 (3.3)
Mixturea
WT + M1 0 (0) 1 (0.7) 0 (0)
WT + M2 6 (3.1) 3 (2.2) 3 (5)
WT + M3 13 (6.7) 1 (0.7) 1 (1.7)
M2 + M3 4 (2.1) 0 (0) 0 (0)
Total
WT 130 (67.0) 131 (93.6) 54 (90.0)
Mutant (M1, M2, M3) 64 (33.0) 9 (6.4) 6 (10.0)
NOTE. Data are no. (%) of patients. WT, wild type.
a Patients with 2 DHPS alleles, which suggested coinfection with 2 P. ji-
rovecii types. The specimens were classified in the corresponding mutant
category (see text).
drugs (158 specimens [7]) and to investigate the possibility of
interhuman transmission within a cluster of patients with PCP
(39 patients [8]). Specimens were stored at20C before anal-
ysis.
Patients’ characteristics. Specific information on demo-
graphic and clinical characteristics and PCP chemoprophylaxis
were obtained from patients’ medical charts. Patients were con-
sidered to have received sulfa prophylaxis if they received sul-
famethoxazole-trimethoprim, pyrimethamine-sulfadoxine, or
dapsone during a period of 3 months preceding the date of
diagnosis of PCP. The duration of prophylaxis ranged from 1
week to the entire 3 months. These definitions were chosen
because the data in the described clusters of PCP suggest that
the incubation period of de novo infection is 3 weeks to 3
months [8]. All chart reviews were done without knowledge of
the DHPS genotyping results.
DHPS extraction and genotyping. DNA was extracted
from specimens using QIAamp DNA Blood Mini Kit (Qiagen).
A region of 318 base pairs spanning the P. jirovecii DHPS bind-
ing site was amplified and genotyped using the PCR single-
strand conformation polymorphism (SSCP) technique as de-
scribed elsewhere [7]. In this technique, each DHPS allele is
identified by a specific SSCP pattern made of 2 DNA bands,
each corresponding to 1 of the 2 single strands of the allele.
Statistical analysis. Possible associations were analyzed by
x2 test. A P value !.05 was considered statistically significant.
Statistical analyses were done with STATA/IC statistical software
(version 10.1; Stata).
RESULTS
Patients. Of the 394 patients included in the study, 194
(49.2%) were from Lyon, 140 (35.5%) were from Lausanne,
and the remaining 60 (15.2%) were from Zurich. Complete
demographic and clinical data were available for 305 patients
(158, 109, and 38 patients from Lyon, Lausanne, and Zurich,
respectively) (Table 1). According to the medical charts, 34
patients were receiving sulfa prophylaxis (14 received pyri-
methamine-sulfadoxine, 10 received sulfamethoxazole-trimeth-
oprim, and 10 received dapsone). The 14 patients who received
pyrimethamine-sulfadoxine were from Lyon; in 3 of the 5 hos-
pitals of this city, pyrimethamine-sulfadoxine was the first-
choice regimen for anti–P. jirovecii prophylaxis. Nevertheless,
this prophylaxis was suboptimal because it was at a dosage
lower than recommended (1 or 3 tablets of 500 mg sulfadoxine
plus 25 mg pyrimethamine every 2 weeks vs 2 tablets per week
[9]). In the 2 other hospitals in Lyon, aerosolized pentamidine
was most frequently used as prophylaxis. By mid-1996, all sus-
ceptible patients in Lyon were given appropriate prophylaxis
with sulfamethoxazole-trimethoprim. Adequate prophylaxis
with dapsone or sulfamethoxazole-trimethoprim was used in
the 2 Swiss hospitals. A review of the entire available medical
history of the patients suggested that no patients had received
sulfa drugs for any purpose other than for PCP, and none had
received sulfadiazine as treatment for toxoplasmosis prior to
the episode of PCP. Except for 2 patients receiving pyrimeth-
amine-sulfadoxine who stopped prophylaxis 7 days before the
diagnosis of PCP was made, all patients were receiving pro-
phylaxis at the time of PCP occurrence. There were no signif-
icant differences in clinical or biologic parameters among the
patients from the different cities and hospitals or between those
who received prophylaxis and those who did not receive pro-
phylaxis.
Genotypes and prevalence of DHPS. Eight different P. ji-
rovecii DHPS genotypes were detected using PCR SSCP for the
394 specimens (Table 2). The predominant genotype observed
among patients from each city was the wild-type allele (67.0%
in Lyon, 93.6% in Lausanne, and 90.0% in Zurich). The re-
maining specimens contained either only 1 mutant genotype
or a mixture of DHPS genotypes, including most often a mutant
and a wild-type allele. The latter category comprised 32 spec-
imens (8.1%) and suggested coinfection with at least 2 P. ji-
rovecii strains. These specimens were classified in the corre-
sponding mutant category in further analyses. Four specimens
displaying a mixture of M2 and M3 genotypes were classified
in the M3 category. The predominant mutant in Lyon was M2
(38 [59.4%] of 64 mutants). The proportion of mutant DHPS
strains was 33.0% in Lyon but was only 6.4% in Lausanne and
10.0% in Zurich. The prevalence of mutant DHPS was signif-
icantly higher in Lyon than in Switzerland (64 [33.0%] of 194
vs 15 [7.5%] of 200; ). In contrast, the difference inP ! .001
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Table 3. Pneumocystis jirovecii Dihydropteroate Synthase
(DHPS) Genotypes in 305 Patients with P. jirovecii Pneumonia
Who Received or Did Not Receive Sulfa Prophylaxis in 3 Euro-
pean Cities
City, DHPS genotype
Received sulfa
prophylaxis (%)
Received no or other
prophylaxis (%)
Lyon (5 hospitals)
WT 4 (20.0) 97 (70.3)
Mutant 16 (80.0) 41 (29.7)
Lausanne
WT 3 (30.0) 98 (99.0)
Mutant 7 (70.0) 1 (1.0)
Zurich
WT 3 (75.0) 31 (91.2)
Mutant 1 (25.0) 3 (8.8)
Alla
WT 10 (29.4) 226 (83.4)
Mutant 24 (69.6) 45 (16.6)
NOTE. Data are no. (%) of patients. WT, wild type.
a .P ! .001
prevalence of mutants between the Zurich and Lausanne hos-
pitals ( ) was not statistically significant. There were noPp .56
significant differences in age, sex, HIV status, HIV risk factor,
and CD4 cell count among patients infected with mutant P.
jirovecii and those infected with wild-type strains.
Association between DHPS mutations and sulfa
prophylaxis. Among the 305 patients with complete medical
charts available, the specimens obtained from patients who
received sulfa prophylaxis were more likely to harbor P. jirovecii
mutant DHPS strains than were those from patients who did
not receive any sulfa prophylaxis (24 [70.6%] of 34 patients vs
45 [16.6%] of 271; ) (Table 3). The proportion of pa-P ! .001
tients receiving sulfa prophylaxis was not significantly higher
in the Lyon hospitals than in the Swiss hospitals (20 [12.7%]
of 158 vs 14 [9.5%] of 147; ). DHPS mutations werePp .48
present in 16.6% of the patients who were not exposed to sulfa
prophylaxis. This proportion was significantly higher in the
Lyon hospitals than in the Swiss hospitals (41 [29.7%] of 138
vs 4 [3.0%] of 133; ).P ! .001
DISCUSSION
In this retrospective study of the prevalence of P. jirovecii mu-
tant DHPS genotypes among patients in 3 cities, we found a
significantly higher prevalence of DHPS mutants in Lyon than
in Zurich and Lausanne. In contrast, there were no significant
differences in the prevalence between Zurich and Lausanne, as
well as among the 5 hospitals in Lyon [7]. Furthermore, we
observed that patients receiving sulfa prophylaxis were more
likely to harbor a mutant P. jirovecii strain than were those not
receiving prophylaxis, that DHPS mutations were also present
in patients who had apparently not been exposed to sulfa drugs,
and that the proportion of the latter category of patients was
significantly higher in the Lyon hospitals than in the Swiss
hospitals. The limitations of the study included the lack of
contemporary data, as well as the lack of clinical information
for 23% of the patients, but there are no reasons to think that
these affected the conclusions drawn.
Geographic variation in allelic frequency at the DHPS locus
among cities in a restricted area, or even within a single city,
has been reported in several countries [10–13]. The proportion
of patients receiving PCP prophylaxis with sulfa drugs was
thought to be the key parameter to explain these variations.
Indeed, the pressure exerted by the sulfa drug can select the
mutant strains within a patient receiving sulfa for prophylaxis
[14, 15]. Selection of the mutations by sulfa drugs was also
strongly supported by the fact that, in the 5 hospitals in Lyon,
the M2 mutation was specifically selected by suboptimal pro-
phylaxis with the combination of sulfadoxine and pyrimeth-
amine, which was used only in this city [7]. However, sulfa
prophylaxis might not be the only explanation, because P. ji-
rovecii mutant strains were also found in the absence of pro-
phylactic or therapeutic exposure to sulfa drugs [5, 11]. Al-
though it is difficult to rule out that these patients have received
any sulfa drugs, such cases are more likely to result from ac-
quisition of a mutated strain via interhuman transmission from
other individuals in whom selection of mutants occurred. Sup-
porting this hypothesis, the place of the PCP diagnosis was an
independent risk factor for the acquisition of a mutant P. ji-
rovecii DHPS genotype, after adjustment for other variables,
including sulfa exposure, in the multivariate analyses [10, 11].
Interhuman transmission might have been direct, but indirect
transmission through carriers such as health care workers, phy-
sicians, or asymptomatic immunosuppressed patients cannot
be ruled out.
The higher prevalence of mutant DHPS in Lyon than in
Switzerland was not because of a higher proportion of patients
receiving prophylaxis. Indeed, the proportion of patients with
no evidence of sulfa exposure that harbored a mutant P. jirovecii
DHPS genotype was significantly higher in the Lyon hospitals,
compared with the Swiss hospitals. Two facts suggest a role of
person-to-person transmission in the acquisition of mutated P.
jirovecii during the study period in Lyon. First, a policy of
isolating patients according to their underlying disease or be-
cause of the occurrence of a PCP episode was not implemented
in 4 of the 5 hospitals. In particular, HIV-infected patients with
PCP were not separated from organ transplant recipients in 1
of the 5 hospitals. In this hospital, we previously reported mo-
lecular evidence of interhuman transmission among a cluster
of 10 renal transplant recipients with PCP [8]. Second, sub-
optimal prophylaxis using Fansidar was the first choice in 3 of
the 5 hospitals in Lyon. Failure of such prophylaxis in 14 pa-
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tients was strictly associated with mutation M2 [7]. Dissemi-
nation of these strains may have provoked secondary cases,
possibly corresponding to the 24 patients with mutation M2
in Lyon without evidence of exposure to sulfa drugs. In contrast,
dissemination of P. jirovecii was prevented by isolation measures
and adequate prophylaxis used in the 2 Swiss hospitals.
The DHPS wild-type genotype was present in the majority
of samples from the 3 cities and the mean prevalence of mutant
genotypes was 20%. This prevalence is within the range of
values reported in Europe—from a low of 3% in Portugal [16]
to a high of 47% in England [17]. A similar prevalence was
reported in Australia (13%) [18] and Japan (29%) [19]. The
limited data from developing countries seem to indicate that
the prevalence may be lower there than in the developed coun-
tries: 0% in Brazil [20] and China [21], 7% in Zimbabwe [22],
and 12% in Thailand [23]. By contrast, the rates reported in
the United States were generally higher, ranging from 26% [3]
to 81% [24]. This difference could be explained at least partially
by the fact that a smaller proportion of patients were receiving
prophylaxis in Europe than in the United States. Indeed, this
proportion was only 12% in our study but was 38% and 64%
in the studies by Huang et al [11] and Kazanjian et al [5],
respectively. Nevertheless, the present study suggests that ac-
quisition of mutant strains by interhuman transmission may
also have played an important role in some studies. The mutant
strains acquired in the absence of sulfa exposure reported [5,
11] may be examples of such interhuman transmission events,
nosocomial or not.
In conclusion, we describe a geographical variation in the
prevalence of the P. jirovecii DHPS mutations, which may be
caused by interhuman transmission in one city, possibly linked
to the absence of measures to prevent nosocomial dissemina-
tion of the fungus and to a suboptimal prophylaxis regimen.
Our results suggest that interhuman transmission may play a
predominant role in P. jirovecii epidemiology in some hospitals.
This should be kept in mind in the perspective of a possible
emergence of P. jirovecii strains resistant to sulfa drugs. In the
absence of isolation measures, interhuman transmission may
accelerate the selection of strains clinically resistant to sulfa
drugs by favoring the accumulation of mutations under the
pressure of sulfa prophylaxis. This may become more pro-
nounced in developing countries because of the widespread use
of sulfa drugs to treat many bacterial diseases.
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